Edgewise Therapeutics reported an insider transaction on March 31, 2026, when Chief Medical Officer Joanne M. Donovan sold 21,338 shares of the company's common stock for an aggregate amount of about $685,308. The disposal was executed at prices ranging from $32.00 to $32.35, according to a Form 4 filing with the Securities and Exchange Commission.
The timing of the sale coincides with the stock trading near its 52-week high of $32.80, following a 94% price advance over the previous six months. The Form 4 indicates the shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan that Donovan adopted on December 26, 2025.
In the same set of filings, Donovan disclosed exercising options to acquire the identical number of shares sold - 21,338 - at an exercise price of $7.08 per share, representing an outlay of $151,073. After completing both the sale and the option exercise, Donovan directly holds 9,597 shares of common stock and retains options to purchase 153,662 shares.
Valuation note
Investment analysis referenced in the filings and related commentary notes that InvestingPro indicates the stock is currently overvalued relative to its Fair Value, listing Edgewise among the more overvalued names tracked on that platform. That assessment sits alongside the recent run-up in the share price.
Clinical results and analyst response
Edgewise has been in the spotlight after presenting long-term data from its MESA open-label extension study. The company reported that participants with Becker muscular dystrophy (BMD) treated with sevasemten maintained stable function over a 3.5-year period. Those results were presented at the 2026 MDA Clinical and Scientific Conference and were characterized by the company as stability in function compared with the declines predicted by BMD natural history studies.
Following the MESA data, several brokerages issued or adjusted analyst opinions and price targets. Raymond James reiterated a Strong Buy rating and set a $46.00 price target. Truist Securities maintained a Buy rating with a $46.00 price target as well. Evercore ISI raised its price target to $45 from $30, citing expected data from the EDG-7500 trial in the first half of 2026. JPMorgan also increased its price target to $45 and retained an Overweight rating, pointing to anticipated catalysts in Edgewise's pipeline, notably EDG-7500.
Context and takeaways
The transactions by the CMO combined a sale under a Rule 10b5-1 plan with a contemporaneous option exercise, leaving Donovan with a modest direct holding and a larger position via outstanding options. Market observers will note the juxtaposition of the insider sale with ongoing optimism from analysts and the stock's recent strong performance. Public filings and analyst statements cited above provide the factual record of the trade, the option exercise, the clinical findings, and the subsequent analyst actions.
While the sale is recorded at an elevated share price point, the filing documents the pre-arranged nature of the sale plan. The company's clinical data and upcoming trial milestones remain the primary items cited by analysts in establishing and increasing price targets.